Cargando…
Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.)
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Diabetes India. Published by Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244409/ https://www.ncbi.nlm.nih.gov/pubmed/32473904 http://dx.doi.org/10.1016/j.dsx.2020.05.030 |
| _version_ | 1783537565267132416 |
|---|---|
| author | Singh, Awadhesh Kumar Gupta, Ritesh Misra, Anoop |
| author_facet | Singh, Awadhesh Kumar Gupta, Ritesh Misra, Anoop |
| author_sort | Singh, Awadhesh Kumar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7244409 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Diabetes India. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72444092020-05-26 Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) Singh, Awadhesh Kumar Gupta, Ritesh Misra, Anoop Diabetes Metab Syndr Letter to the Editor Diabetes India. Published by Elsevier Ltd. 2020 2020-05-23 /pmc/articles/PMC7244409/ /pubmed/32473904 http://dx.doi.org/10.1016/j.dsx.2020.05.030 Text en © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Singh, Awadhesh Kumar Gupta, Ritesh Misra, Anoop Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title | Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title_full | Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title_fullStr | Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title_full_unstemmed | Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title_short | Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.) |
| title_sort | reply to the letter of mahajan and gaur in response to the article: comorbidities in covid-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (singh et al.) |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244409/ https://www.ncbi.nlm.nih.gov/pubmed/32473904 http://dx.doi.org/10.1016/j.dsx.2020.05.030 |
| work_keys_str_mv | AT singhawadheshkumar replytotheletterofmahajanandgaurinresponsetothearticlecomorbiditiesincovid19outcomesinhypertensivecohortandcontroversieswithreninangiotensinsystemblockerssinghetal AT guptaritesh replytotheletterofmahajanandgaurinresponsetothearticlecomorbiditiesincovid19outcomesinhypertensivecohortandcontroversieswithreninangiotensinsystemblockerssinghetal AT misraanoop replytotheletterofmahajanandgaurinresponsetothearticlecomorbiditiesincovid19outcomesinhypertensivecohortandcontroversieswithreninangiotensinsystemblockerssinghetal |